Other headache syndrome
Methodology & AI Transparency ⓘ
Other headache syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Other headache syndrome (ICD-10-CM G44.89), Migraine & Headache Disorders protocols prioritize preventive threshold assessment in Other headache syndrome (G44.89: (>= 4 monthly) paired with baseline and interval Monthly Headache Days in Other headache syndrome (G44.89: (MHD)) assessment.
- 2 Real-world patient consensus: Mapped to Migraine & Headache Disorders under ICD-10-CM G44.89 for Other headache syndrome clinical workups.
- 3 Typical cash cost range: Differential triage of Other headache syndrome (G44.89) utilizes preventive threshold assessment in Other headache syndrome (G44.89: (>= 4 monthly).
- 4 Top reported side effects / signs: Longitudinal Other headache syndrome monitoring tracks Monthly Headache Days in Other headache syndrome (G44.89: (MHD)) toward < 2 days/month on prevention (G44.89).
Ask our AI Specialists anything about Other headache syndrome
What Is Other headache syndrome?
For patients presenting with Other headache syndrome (ICD-10-CM G44.89), Migraine & Headache Disorders protocols prioritize preventive threshold assessment in Other headache syndrome (G44.89: (>= 4 monthly) paired with baseline and interval Monthly Headache Days in Other headache syndrome (G44.89: (MHD)) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
In Other headache syndrome (G44.89), physiological disruption stems from trigeminovascular pathway activation [Other headache syndrome G44.89], informing Migraine & Headache Disorders protocols that track MIDAS Disability Score [Other headache syndrome G44.89] (Grade I (0 – 5) (G44.89)).
Common Symptoms & Clinical Signs
- • Presentation of Other headache syndrome (G44.89): visual aura [Other headache syndrome G44.89]
- • Secondary Other headache syndrome clinical sign: nausea, gastric stasis, in Other headache syndrome (G44.89: or worsening pain)
- • Symptom flares in Other headache syndrome correlating with Monthly Headache Days in Other headache syndrome (G44.89: (MHD)) deviation outside < 2 days/month on prevention (G44.89)
- • Functional migraine & headache impact requiring preventive threshold assessment in Other headache syndrome (G44.89: (>= 4 monthly) evaluation (G44.89)
Other headache syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G44.89 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Migraine & Headache Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Monthly Headache Days in Other headache syndrome (G44.89: (MHD)) | < 2 days/month on prevention (G44.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MIDAS Disability Score [Other headache syndrome G44.89] | Grade I (0 – 5) (G44.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: RBC Magnesium & in Other headache syndrome (G44.89: Riboflavin Status) | RBC Mg 5.0 – 6.4 mg/dL (G44.89) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other headache syndrome
Treatment selection for Other headache syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other headache syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other headache syndrome Patient Community & “People Like Me” Threads
Filter Other headache syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.